Featured Research

from universities, journals, and other organizations

New safety test predicts reactions to novel drugs and cosmetics

Date:
May 27, 2013
Source:
Newcastle University
Summary:
A simple lab-based skin test which eliminates the risk of adverse reactions to new drugs, cosmetics and household chemicals has been developed. It uses real human skin and immune cells to show any reaction such as a rash or blistering indicating a wider immune response within the body.

Professor Anne Dickinson of Newcastle University and Alcyomics.
Credit: Newcastle University, UK

A simple lab-based skin test which eliminates the risk of adverse reactions to new drugs, cosmetics and household chemicals has been developed by a Newcastle University team.

It uses real human skin and immune cells to show any reaction such as a rash or blistering indicating a wider immune response within the body.

The development is timely as it offers a reliable alternative for the cosmetic industry as a ban on the sale of any cosmetic product tested on animals came into effect across Europe in March.

Professor Anne Dickinson from the Institute of Cellular Medicine recently presented the technology at the In-Vitro Testing Industrial Platform (IVTIP) conference in Brussels. She said: "This skin assay offers an accurate and rapid alternative to animal testing and provides the bridge between the laboratory tests for novel drugs and the first stage of clinical trials in humans.

"It is accurate and faster than anything currently around and can save companies time and resources. The test identifies drugs or products which are likely to cause a reaction or just not work effectively in humans."

The test called SkimuneTM, which is trademarked and has a patent pending, has been successfully tested by a number of large pharmaceutical companies on drugs in development and provides a reliable result within two weeks.

By revealing skin sensitisation or an adverse reaction that may not be identified by use of an animal or computer model, the assay can provide vital information which will allow a drug company to make informed decisions earlier saving significant development costs.

Professor Dickinson said: "We've already shown this works as a way of testing new drugs for adverse immune reactions that can't be identified when tested in animal models."

Working with the National Institute of Biological Standards and Control (NIBSC) the Newcastle team have been testing monoclonal antibodies for adverse responses. Professor Dickinson added: "Our Skimune™ test would have predicted the terrible outcome at Northwick Park in 2006. Then six men taking part in a clinical trial had severe reactions to a monoclonal antibody resulting in organ failure. Previous laboratory and animal research gave no indication that this was likely to occur.

"Our test would have picked up the risk because it is a skin-based model of the human immune response."

The skin assay has been developed using cells isolated from blood samples from a range of healthy volunteers. Differentiated into dendritic cells which activate the T-cells, these in turn create a cytokine storm. Useful for fighting infection, if this immune response goes unchecked it can be extremely harmful to the individual. SkimuneTM provides a histology skin damage read out enabling the severity and potency of reaction to be gauged.

Professor Richard Stebbings, Principal Scientist at NIBSC welcomed the development adding: "This assay offers a valuable alternative to animal models, used for safety testing of biological medicines and which are often poorly predictive of human responses."

Professor Anne Dickinson has spent 20 years working to understand how we prevent the body rejecting donor tissue such as bone marrow. This technology has been developed from a skin explant model for predicting a potentially serious complication of bone marrow transplantation, 'graft versus host' disease -- a common complication following the transplant. It has been supported with a grant from the UK's innovation agency, the Technology Strategy Board for the development of a prototype.

As well as patent pending the SkimuneTM test, the Newcastle University team have set up a company Alcyomics Limited which aims to take the technology forward to offer personalised medicine, enabling an individual to be tested for drug responses.

More information on the technology can be found on the Alcyomics Limited website: http://www.alcyomics.com/


Story Source:

The above story is based on materials provided by Newcastle University. Note: Materials may be edited for content and length.


Cite This Page:

Newcastle University. "New safety test predicts reactions to novel drugs and cosmetics." ScienceDaily. ScienceDaily, 27 May 2013. <www.sciencedaily.com/releases/2013/05/130527231911.htm>.
Newcastle University. (2013, May 27). New safety test predicts reactions to novel drugs and cosmetics. ScienceDaily. Retrieved September 3, 2014 from www.sciencedaily.com/releases/2013/05/130527231911.htm
Newcastle University. "New safety test predicts reactions to novel drugs and cosmetics." ScienceDaily. www.sciencedaily.com/releases/2013/05/130527231911.htm (accessed September 3, 2014).

Share This



More Health & Medicine News

Wednesday, September 3, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Snack Attack: Study Says Action Movies Make You Snack More

Snack Attack: Study Says Action Movies Make You Snack More

Newsy (Sep. 2, 2014) You're more likely to gain weight while watching action flicks than you are watching other types of programming, says a new study published in JAMA. Video provided by Newsy
Powered by NewsLook.com
U.N. Says Ebola Travel Restrictions Will Cause Food Shortage

U.N. Says Ebola Travel Restrictions Will Cause Food Shortage

Newsy (Sep. 2, 2014) The U.N. says the problem is two-fold — quarantine zones and travel restrictions are limiting the movement of both people and food. Video provided by Newsy
Powered by NewsLook.com
Doctors Fear They're Losing Battle Against Ebola

Doctors Fear They're Losing Battle Against Ebola

AP (Sep. 2, 2014) As a third American missionary is confirmed to have contracted Ebola in Liberia, doctors on the ground in West Africa fear they're losing the battle against the outbreak. (Sept. 2) Video provided by AP
Powered by NewsLook.com
Tech Giants Bet on 3D Headsets for Gaming, Healthcare

Tech Giants Bet on 3D Headsets for Gaming, Healthcare

AFP (Sep. 2, 2014) When Facebook acquired the virtual reality hardware developer Oculus VR in March for $2 billion, CEO Mark Zuckerberg hailed the firm's technology as "a new communication platform." Duration: 02:24 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins